WallStreetZenWallStreetZen

NASDAQ: BCRX
Biocryst Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BCRX

Based on 7 analysts offering 12 month price targets for Biocryst Pharmaceuticals Inc

Min Forecast
$9.00-3.54%
Avg Forecast
$21.86+134.27%
Max Forecast
$32.00+242.98%

Should I buy or sell BCRX stock?

Based on 7 analysts offering ratings for Biocryst Pharmaceuticals Inc.

Buy
Strong Buy
2 analysts 28.57%
Buy
4 analysts 57.14%
Hold
1 analysts 14.29%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Strong Buy" agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their BCRX stock forecasts and price targets.

BCRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-30
lockedlocked$00.00+00.00%2025-12-15Find Out Why
lockedlocked$00.00+00.00%2025-11-05Find Out Why
lockedlocked$00.00+00.00%2025-11-04Find Out Why
lockedlocked$00.00+00.00%2025-11-04
TD Cowen
Bottom 37%
37
Strong BuyReinstates$30.00+221.54%2025-10-15Find out why
Cantor Fitzgerald
Top 12%
89
Strong BuyMaintains$26.00+178.67%2025-10-15Find out why

1 of 1

Forecast return on equity

Is BCRX forecast to generate an efficient return?

Company
-350.5%
Industry
62.65%
Market
179.39%
BCRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BCRX forecast to generate an efficient return on assets?

Company
81.23%
Industry
31.76%
BCRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BCRX earnings per share forecast

What is BCRX's earnings per share in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$0.39-68.79%
Avg 2 year Forecast
$0.59-53.42%
Avg 3 year Forecast
$0.51-59.25%
BCRX's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

BCRX revenue forecast

What is BCRX's revenue in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$663.8M-24.13%
Avg 2 year Forecast
$747.1M-14.61%
Avg 3 year Forecast
$892.4M+2%
BCRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BCRX earnings growth forecast

How is BCRX forecast to perform vs Biotechnology companies and vs the US market?

Company
-23.25%
Industry
11.92%
Market
35.94%
BCRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
BCRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
BCRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

BCRX revenue growth forecast

How is BCRX forecast to perform vs Biotechnology companies and vs the US market?

Company
0.66%
Industry
35.12%
Market
13.11%
BCRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BCRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BCRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BCRX$9.33$21.86+134.27%Buy
ELVN$38.83$50.50+30.05%Buy
VCYT$30.01$45.17+50.51%Buy
IRON$60.09$101.00+68.08%Strong Buy
BEAM$22.19$51.44+131.83%Buy
View Top Biotech Stocks

Biocryst Pharmaceuticals Stock Forecast FAQ

Is Biocryst Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: BCRX) stock is to Buy BCRX stock.

Out of 7 analysts, 2 (28.57%) are recommending BCRX as a Strong Buy, 4 (57.14%) are recommending BCRX as a Buy, 1 (14.29%) are recommending BCRX as a Hold, 0 (0%) are recommending BCRX as a Sell, and 0 (0%) are recommending BCRX as a Strong Sell.

If you're new to stock investing, here's how to buy Biocryst Pharmaceuticals stock.

What is BCRX's earnings growth forecast for 2026-2028?

(NASDAQ: BCRX) Biocryst Pharmaceuticals's forecast annual earnings growth rate of -23.25% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.94%.

Biocryst Pharmaceuticals's earnings in 2026 is $263,861,000.On average, 12 Wall Street analysts forecast BCRX's earnings for 2026 to be $98,614,804, with the lowest BCRX earnings forecast at $2,457,846, and the highest BCRX earnings forecast at $208,841,676. On average, 12 Wall Street analysts forecast BCRX's earnings for 2027 to be $147,194,884, with the lowest BCRX earnings forecast at $2,457,846, and the highest BCRX earnings forecast at $279,141,090.

In 2028, BCRX is forecast to generate $128,761,038 in earnings, with the lowest earnings forecast at $27,036,307 and the highest earnings forecast at $323,909,001.

What is BCRX's revenue growth forecast for 2026-2028?

(NASDAQ: BCRX) Biocryst Pharmaceuticals's forecast annual revenue growth rate of 0.66% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.11%.

Biocryst Pharmaceuticals's revenue in 2026 is $874,837,000.On average, 12 Wall Street analysts forecast BCRX's revenue for 2026 to be $166,473,927,537, with the lowest BCRX revenue forecast at $157,302,148,864, and the highest BCRX revenue forecast at $174,336,526,974. On average, 12 Wall Street analysts forecast BCRX's revenue for 2027 to be $187,363,111,177, with the lowest BCRX revenue forecast at $168,726,117,105, and the highest BCRX revenue forecast at $211,111,421,885.

In 2028, BCRX is forecast to generate $223,806,949,269 in revenue, with the lowest revenue forecast at $177,885,355,747 and the highest revenue forecast at $251,051,420,620.

What is BCRX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: BCRX) forecast ROA is 81.23%, which is higher than the forecast US Biotechnology industry average of 31.76%.

What is BCRX's Price Target?

According to 7 Wall Street analysts that have issued a 1 year BCRX price target, the average BCRX price target is $21.86, with the highest BCRX stock price forecast at $32.00 and the lowest BCRX stock price forecast at $9.00.

On average, Wall Street analysts predict that Biocryst Pharmaceuticals's share price could reach $21.86 by Jan 30, 2027. The average Biocryst Pharmaceuticals stock price prediction forecasts a potential upside of 134.27% from the current BCRX share price of $9.33.

What is BCRX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: BCRX) Biocryst Pharmaceuticals's current Earnings Per Share (EPS) is $1.26. On average, analysts forecast that BCRX's EPS will be $0.39 for 2026, with the lowest EPS forecast at $0.01, and the highest EPS forecast at $0.83. On average, analysts forecast that BCRX's EPS will be $0.59 for 2027, with the lowest EPS forecast at $0.01, and the highest EPS forecast at $1.11. In 2028, BCRX's EPS is forecast to hit $0.51 (min: $0.11, max: $1.29).

What is BCRX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: BCRX) forecast ROE is -350.5%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.